TrialCardiology journal2022

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC).

Krzysztof Ozierański et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.